AnaptysBio (ANAB) AI Stock Analysis

• Market Cap: $1.21B
• Dividend Yield: N/A
• Average Volume (3M): 629.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: 196.42%
• EPS Growth: 53.92%
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.52
• Shares Outstanding: 27,688,470
• 10 Day Avg. Volume: 420,184
• 30 Day Avg. Volume: 629,022
• PEG Ratio: 0.16
• Price to Book (P/B): 5.30
• Price to Sales (P/S): 4.12
• P/FCF Ratio: -2.77
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 5.82
• Enterprise Value/Gross Profit: 59.88
• Enterprise Value/Ebitda: -215.76
• 1Y Price Target: $65.14
• Price Target Upside: 44.92% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -1.69
• Revenue Forecast (FY): $204.72M

• Rating: 49 Neutral
• Price Target: $44.00 ▼(-2.11% Downside)

AnaptysBio's overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and a precarious balance sheet. While technical indicators show bullish momentum, the stock's valuation remains unattractive due to negative earnings. Corporate events present mixed implications, with legal challenges offset by strategic initiatives like stock buybacks and business separation plans.

Positive Factors

Revenue Growth

AnaptysBio's strong revenue growth indicates successful market penetration and product demand, providing a foundation for future profitability.

Strategic Initiatives

The $100M stock repurchase plan reflects confidence in the company's financial health and commitment to enhancing shareholder value.

Business Separation Plans

The business separation plan aims to unlock shareholder value by focusing on distinct strategic and financial objectives for each entity.

Negative Factors

Legal Challenges

Ongoing legal disputes with TESARO and GSK could disrupt strategic partnerships and impact future revenue from collaborations.

Profitability Challenges

Persistent profitability challenges, as indicated by negative margins, suggest operational inefficiencies that could hinder long-term sustainability.

Balance Sheet Health

Negative equity and a weak balance sheet pose solvency risks, limiting financial flexibility and potential for future investments.

AnaptysBio Business Overview & Revenue Model

Company Description

AnaptysBio (ANAB) is a clinical-stage biotechnology company focused on the discovery and development of antibody therapeutics for the treatment of various diseases, particularly in the fields of immunology and oncology. The company leverages its proprietary drug discovery platform to create novel therapeutic antibodies aimed at addressing unmet medical needs in conditions such as autoimmune diseases and cancer. AnaptysBio’s pipeline includes several product candidates that are in various stages of clinical trials, showcasing its commitment to advancing innovative treatments.

How the Company Makes Money

AnaptysBio generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, who seek to leverage AnaptysBio's proprietary antibody discovery platform and therapeutic candidates. The company receives milestone payments tied to the progress of drug development and potential royalties on sales of products developed from their collaborations. Additionally, AnaptysBio may generate revenue from grants or research funding, although the bulk of its earnings are expected to come from successful partnerships that lead to commercialized therapies.

AnaptysBio Financial Statement Overview

Summary

AnaptysBio faces significant financial challenges, with persistent losses and a weak balance sheet. The income statement shows a negative net profit margin and declining gross profit margin. The balance sheet reveals negative stockholders' equity and poor returns for shareholders. Cash flow analysis indicates cash burn despite some improvement in free cash flow growth.

Income Statement

AnaptysBio's income statement shows significant challenges with profitability. The company has a negative net profit margin of -49.94% in the TTM, indicating substantial losses relative to revenue. Despite a strong revenue growth rate of 37.60% in the TTM, the EBIT and EBITDA margins remain negative, reflecting ongoing operational inefficiencies. The gross profit margin has decreased from 97.37% in 2024 to 54.61% in the TTM, suggesting increased cost pressures.

Balance Sheet

The balance sheet reveals a precarious financial position with negative stockholders' equity in the TTM, resulting in an undefined debt-to-equity ratio. This indicates potential solvency issues. The return on equity is significantly negative at -1101.24%, highlighting poor returns for shareholders. The equity ratio is also negative, reflecting a concerning capital structure.

Cash Flow

Cash flow analysis shows improvement in free cash flow growth at 13.46% in the TTM, but the operating cash flow remains negative, indicating cash burn. The operating cash flow to net income ratio is -3.80, suggesting that cash outflows are not being adequately covered by income. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is slightly better aligned with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	169.47M	91.28M	17.16M	10.29M	63.17M	75.00M
Gross Profit	16.47M	-72.56M	-115.13M	-78.51M	-35.32M	-5.03M
EBITDA	-4.57M	-92.74M	-156.42M	-105.26M	-55.71M	-19.37M
Net Income	-84.63M	-145.23M	-163.62M	-128.72M	-57.80M	-19.93M
Balance Sheet
Total Assets	353.10M	483.83M	452.39M	610.38M	643.07M	416.55M
Cash, Cash Equivalents and Short-Term Investments	248.96M	385.37M	390.90M	441.24M	548.10M	393.65M
Total Debt	346.45M	369.46M	17.81M	19.45M	20.95M	342.00K
Total Liabilities	382.51M	412.97M	364.29M	348.28M	286.64M	19.82M
Stockholders Equity	-29.42M	70.87M	88.10M	262.10M	356.43M	396.73M
Cash Flow
Free Cash Flow	-145.32M	-135.69M	-121.61M	-73.95M	-47.29M	-14.73M
Operating Cash Flow	-144.97M	-135.34M	-120.80M	-73.59M	-45.92M	-14.16M
Investing Cash Flow	125.14M	95.40M	144.75M	-394.85M	38.84M	94.47M
Financing Cash Flow	-61.91M	127.05M	-59.30M	44.02M	252.30M	-879.00K

AnaptysBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 44.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Positive. The current price of 44.95 is above the 20-day moving average (MA) of 40.65, above the 50-day MA of 36.74, and above the 200-day MA of 25.14, indicating a bullish trend. The MACD of 2.70 indicates Negative momentum. The RSI at 72.49 is Negative, neither overbought nor oversold. The STOCH value of 68.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANAB.

AnaptysBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KROS	72 Outperform	$655.93M	14.16	10.43%	―	37798.31%	―
CMPX	60 Neutral	$914.21M	―	-37.82%	―	-100.00%	-28.79%
MGTX	54 Neutral	$679.34M	―	-611.42%	―	96.83%	-61.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANAB	49 Neutral	$1.21B	―	-308.02%	―	196.42%	53.92%
OLMA	46 Neutral	$2.23B	―	-59.22%	―	―	17.23%
TERN	45 Neutral	$3.83B	―	-29.12%	―	―	12.45%

AnaptysBio Corporate Events

AnaptysBio Files Legal Complaint Against GSK and Tesaro

On November 20, 2025, AnaptysBio filed a complaint in Delaware Chancery Court against TESARO, Inc. and GlaxoSmithKline (GSK), alleging breaches of their Collaboration and Exclusive License Agreement. The dispute centers around the development and commercialization of dostarlimab, a promising PD-1 antagonist used in cancer treatment. AnaptysBio claims that Tesaro and GSK have violated exclusivity and diligence obligations by conducting clinical trials with competing products, thus undermining dostarlimab’s commercial potential. This legal action seeks to reclaim rights to dostarlimab and address the alleged breaches, which have significant implications for AnaptysBio’s strategic positioning and stakeholder interests.

AnaptysBio Sues TESARO Over License Agreement Breach

On November 20, 2025, AnaptysBio filed a Verified Complaint against TESARO, Inc. in Delaware Chancery Court, alleging breach of their Collaboration and Exclusive License Agreement and tortious interference by GlaxoSmithKline, TESARO’s parent company. AnaptysBio claims TESARO violated exclusivity obligations by engaging in clinical trials with competing PD-1 antagonists and failed to maximize commercial returns for Jemperli. Previously, in 2020, AnaptysBio filed a similar complaint against GSK, resulting in a settlement with increased royalties. Despite attempts at resolution, TESARO counter-sued AnaptysBio, seeking injunctive relief. An expedited trial is set for July 2026, with ongoing milestone and royalty payments to AnaptysBio.

AnaptysBio Expands Stock Repurchase Plan by $100M

On November 21, 2025, AnaptysBio announced an amendment to its Stock Repurchase Plan, allowing for an additional $100 million in stock buybacks, supplementing the $6.4 million remaining under the existing $75 million plan. This strategic move is set against the backdrop of AnaptysBio’s anticipated financial position, expecting to end 2025 with approximately $300 million in cash and investments, bolstered by a potential $75 million milestone payment from GSK. The repurchase plan, expiring on March 31, 2026, reflects AnaptysBio’s efforts to enhance shareholder value while navigating market conditions and corporate strategies.

AnaptysBio Announces Business Separation Plans

On September 29, 2025, AnaptysBio announced plans to separate its business into two independent, publicly traded companies by the end of 2026. This strategic move aims to maximize shareholder value by allowing investors to align with each company’s distinct strategic and financial objectives. The separation will create a Royalty Management Company to manage substantial royalties and a Biopharma Company focused on developing and commercializing therapeutics. This decision reflects AnaptysBio’s commitment to unlocking and maximizing value for its stakeholders.